Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) EV-to-EBITDA : -0.96 (As of May. 08, 2024)

Clarus Therapeutics Holdings EV-to-EBITDA Chart

Competitive Comparison of Clarus Therapeutics Holdings's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Clarus Therapeutics Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clarus Therapeutics Holdings's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Clarus Therapeutics Holdings's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Clarus Therapeutics Holdings's EV-to-EBITDA falls into.

Clarus Therapeutics Holdings EV-to-EBITDA Calculation

Clarus Therapeutics Holdings's EV-to-EBITDA for today is calculated as:

Clarus Therapeutics Holdings's current Enterprise Value is $21.41 Mil.
Clarus Therapeutics Holdings's EBITDA for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22.25 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clarus Therapeutics Holdings  (OTCPK:CRXTQ) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Clarus Therapeutics Holdings's PE Ratio for today is calculated as:

Clarus Therapeutics Holdings's share price for today is $0.0014.
Clarus Therapeutics Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.300.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Clarus Therapeutics Holdings EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Clarus Therapeutics Holdings's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Business Description